Of miR-3156-3p at the protein level but not the mRNA level. SLC6A6 (also referred to as TauT) is a high-affinity, low-capacity, multi-pass membrane protein that transports taurine and -alanine in a Na+- and Cl–dependent manner . SLC6A6 signaling has also been shown to affect cell proliferation and cell SB 202190 web survival . Han andcolleagues demonstrated that SLC6A6 overexpression protects kidney cells against cisplatin-induced cell death through p53 activation [17, 18]. A recent study found that SLC6A6 plays an important role in the maintenance of side population cells and their cancer stem cell properties, including enhanced prosurvival activity, tumor initiation and chemoresistance in colorectal cancer . Tastesen et al. showed that knockdown of TauT leads to a significant increase in apoptosis following cisplatin exposure and that cisplatin resistance correlated with increased TauT expression/activity . Accordingly, S ensen BH et al. found that acquired resistance in human ovarian A2780 cancer cells correlates with increased TauT activity . Consistent with these reports,Xia et al. Virology Journal (2017) 14:Page 7 ofFig. 4 (See legend on next page.)Xia et al. Virology Journal (2017) 14:Page 8 of(See figure on previous page.) Fig. 4 miR-3156-3p downregulates SLC6A6 expression at the post-transcriptional level in cervical cancer cells. a Protein level of SLC6A6 was detected by Western blot in Caski and SiHa cells transfected with miR-3156-3p inhibitor and mimics along with corresponding negative controls, respectively. b SLC6A6 mRNA level was examined by qRT-PCR in Caski and SiHa cells transfected with a miR-3156-3p inhibitor, mimics and corresponding controls. c HEK293 cells were co-transfected with miR-3156-3p and WT or Mut SLC6A6 3’UTR luciferase reporter construct. (**p < 0.01 vs. controls, *p < 0.05 vs. controls)Fig. 5 SLC6A6 expression in cervical cancer tissues. a SLC6A6 mRNA level was examined by qRT-PCR in cervical cancer and normal cervical tissue. b Immunohistochemical staining of the anti-SLC6A6 antibody in cervical cancer and normal cervical tissues. Strong SLC6A6 immunoreactivity was found in both the cytomembrane and cytoplasm in tumor tissues but not in the normal cervix tissues (scale bar, 100 m). (**p < 0.01, *p < 0.05)Xia et al. Virology Journal (2017) 14:Page 9 ofFig. 6 Promoter methylation of SLC6A6 in cervical cancer cell lines and tissue samples detected with BGS. a BGS analysis of the SLC6A6 promoter in CC cell lines. Each circle is one CpG site and filled circles are methylated CpG sites. There are 49 CpG sites in the BGS region. b The SLC6A6 methylation rate in cervical cancer cell lines and tissue samples. The methylation ratio of Hela, SiHa, Caski, and HT-3 cells as well as cervical cancer tissues and normal cervix tissues was 3.7 , 16.0 , 14.3 , 11.2 , 0.7 , 9.2 and 12.9 , respectivelyour study showed that both mRNA and protein expression levels of SLC6A6 were significantly higher in CC tissues compared to normal cervical tissues, and SLC6A6 may play an important role in cervical carcinogenesis. However, the regulation mechanism PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28212752 of SLC6A6 expression is still less understood and require further study. Related researches found SLC6A6 gene could be repressed by the p53 tumour suppressor gene and be transactivated by proto-oncogenes such as WT1, c-Jun, and c-Myb [17, 22]. Our findings suggest the expression of SLC6A6 was regulated by miR-3156-3p at posttranscriptional level in vitro. Additionally, SL.